EMA gives approval for new treatment in fight against Covid

Sotrovimab is a monoclonal antibody, man-made proteins that act like human antibodies, which is designed to attach to the spike protein of SARS-CoV-2, limiting the ability of the virus to enter the body’s cells.

The European Medicines Agency (EMA) has given approval for sotrovimab to be used to treat Covid-19 in adults and adolescents, GlaxoSmithKline plc (GSK) and Vir Biotechnology, have announced. 

Sotrovimab is a monoclonal antibody, man-made proteins that act like human antibodies, which is designed to attach to the spike protein of SARS-CoV-2, limiting the ability of the virus to enter the body’s cells.